Monoclonal Antibody to CD150 (Clone IPO-3)

Background
Revealing the molecular signals involved in B and T cell activation is critical to the future discovery of therapeutics that can augment cell-mediated immune responses to disease.^1,2,3 CD150 is a type I transmembrane glycoprotein that is involved in signal transduction of antigen specific responses in B and T cells. It is expressed by activated B cells isolated from tonsils and peripheral blood, B cells in germinal centers and mantle zone of lymph nodes, immature thymocytes, and CD45RO+CD45RA- subpopulation of T cells.^4,5 This antibody has been used to detect CD150 in neoplastic cells from diffuse large B-cell lymphoma, Hodgkin’s disease, hairy cell leukemia, and some tumors of ectodermal origin.⁶

Reference
1. Mikhalap, S.V., Shlapatska, L.M., Yurchenko, O.V., et al. The adaptor protein SH2D1A regulates signaling through CD150 (SLAM) in B cells. Blood 104(13) 4063-4070 (2004).
2. Mikhalap, S.V., Shlapatska, L.M., Berdova, A.G., et al. CDw150 associates with src-homology 2-containing inositol phosphatase and modulates CD95-mediated apoptosis. J Immunol 162 5719-5727 (1999).
3. Shlapatska, L.M., Mikhalap, S.V., Berdova, A.G., et al. CD150 association with either the SH2-containing inositol phosphatase or the SH2-containing protein tyrosine phosphatase is regulated by the adaptor protein SH2D1A. J Immunol 166 5480-5487 (2001).
4. Cocks, B.G., Chang, C.J., Carballido, J.M., et al. A novel receptor involved in T-cell activation. Nature 376 260-263 (1995).
5. Sidorenko, S.P., Clark, E.A. Characterization of a cell surface glycoprotein IPO-3, expressed on activated human B and T lymphocytes. J Immunol 151 4614-4624 (1993).
6. Pinchouk, V.G., Sidorenko, S.P., Gluzman, D.F., et al. Monoclonal antibodies IPO-3 and IPO-10 against human B cell differentiation antigens. Anticancer Res 8 1377-1380 (1988).